Introduction {#s0001}
============

Multidrug-resistant *Mycobacterium tuberculosis* (MDR-TB, resistant to at least two of the most powerful first-line anti-TB drugs, isoniazid and rifampin) remains a critical global public health problem due to its high treatment failure rate.[@cit0001]--[@cit0003] According to the latest 2019 report from the World Health Organization (WHO), there were approximately10millionnew cases of TB worldwide, and approximately 1.2 million HIV-negative patients died of tuberculosis. China has the second highest MDR-TB burden, after only India, with approximately 120,000 cases of MDR-TB per year. A national survey of drug-resistant tuberculosis in China showed that the incidence of TB is 5.7%, and 25.6% of retreated patients were infected with MDR-TB, significantly higher than global average level.[@cit0004] The large number of patients with MDR-TB hinders the effective prevention and control of TB in China.[@cit0005],[@cit0006]

Pyrazinamide (PZA) is an important first-line anti-TB drug, with effective bactericidal activity against both drug-sensitive and MDR strains. As a prodrug, PZA is converted by *pncA*-encoded pyrazinamidase (PZase) into pyrazinoic acid (POA) to exhibit bactericidal activities.[@cit0007] The accumulation of POA in cells results in cytoplasmic acidification, which depletes cellular membrane potentials, inhibits various intracellular targets, and eventually leads to cell death.[@cit0008] PZA is effective against persistent bacteria in macrophages, which cannot be killed by other anti-TB drugs. Due to its unique antibacterial activity, PZA reduces the treatment time from 12months to6monthswhen it is combined with isoniazid and rifampicin. Studies have shown that72-98%ofPZAresistance is due to *pncA* mutations,[@cit0009]--[@cit0011] which are highly diverse and scattered in open reading frames and upstream regulatory regions.[@cit0012] In addition to *pncA* mutations, other mechanisms can cause PZA resistance. For example, mutations in *rpsA*, which encodes 30S ribosomal S1 proteins, can alter the POA binding site, causing PZA resistance.[@cit0013] Some studies have shown that *panD* is associated with PZA resistance.[@cit0011] Researchers are still debating the role of *rpsA* and *panD* mutations in PZA resistance, and more experimental data are needed to clarify the contributions of *rpsA* and *panD* to PZA resistance.

PZA has antibacterial activity only at a low pH; thus, an acidic environment is needed for PZA susceptibility tests. Due to the complex procedures and the failure probability of PZA susceptibility tests, only a few laboratories perform these experiments.[@cit0014] However, previous studies have shown that approximately16%of TB patients are PZA resistant. Specifically, the PZA resistance rate is 2--7.5% in non-MDR-TB patients and 36--85% in MDR-TB patients.[@cit0015],[@cit0016] Therefore, the reliable prediction of PZA resistance before treatment facilitates the development of more effective treatments. As the most populous region in China, Henan has the largest number of patients with TB and MDR-TB in the country, making it a hotspot for TB prevention. While PZA is widely used to treat MDR-TB patients, few studies have been conducted to investigate the prevalence of PZA resistance in MDR strains in Henan. In this study, we investigated PZA resistance in MDR-TB patients in Henan and analysed the mutation patterns of PZA resistance-related genes. Moreover, we observed the correlations between PZA resistance and treatment outcomes.

Materials and Methods {#s0002}
=====================

Sample Source {#s0002-s2001}
-------------

MDR-TB patients from 10 regions of Henan during 2018 were included in this study. The patients were followed upfor2years, with monthly sputum smears and *Mycobacterium tuberculosis* cultures during treatment. The study was approved by the Medical Ethics Committee of Henan Provincial Center for Disease Control and Prevention (Number: 2014-KY-012-01). All patients provided informed consent, and this study was conducted in accordance with the Declaration of Helsinki. We collected patient information from medical records. Retreated patients were defined as those receiving more than 1 month of irregular chemotherapy for tuberculosis before presenting at our hospitals.

Drug Susceptibility Testing (DST) {#s0002-s2002}
---------------------------------

Drug susceptibility testing was performed with WHO-recommended proportion method. The drug concentrations in Lowenstein-Jensenmediumwere 0.2 μg/ml isoniazid (INH), 40 μg/ml rifampicin (RIF), 4μg/ml streptomycin (SM), 2 μg/ml ethambutol (EMB),30 μg/ml kanamycin (KAM), 30 μg/ml amikacin (AMK), 2 μg/ml levofloxacin (OFLX), 1 μg/ml p-aminosalicylic acid (PAS), 40 μg/ml capreomycin (CAM), and 40 μg/ml prothionamide (PTO).Resistant strains were considered when more colonies (\>1%) were growing on the drug-containing medium than on the control medium. Bactec MGIT 960 was used for the PZA susceptibility test, and the concentration of PZA in the liquid medium was 100μg/mL. For strains with inconsistent results between DST and DNA sequencing, the tests were repeated, and the minimum inhibitory concentration (MIC) in liquid 7H9 medium was measured. Strains resistant to both isoniazid and rifampicin were defined as MDR strains. In addition to MDR, strains resistant to levofloxacin and at least one second-line injectable anti-tuberculosis drug (amikacin, capreomycin, or kanamycin) were considered extensively drug-resistant (XDR) strains.

DNA Extraction and PCR (Review 1), Sequencing and Characterization of Mutations in *pncA, rpsA* and *panD* (Review 2) {#s0002-s2003}
---------------------------------------------------------------------------------------------------------------------

Fresh cultured bacteria on Lowenstein-Jensen medium were scraped into500 μL of Tris-EDTA (TE) buffer, inactivated at 85°C for30min, boiled for 5min, and then centrifuged for later use.[@cit0017] Crude DNA extract was used as the template for polymerase chain reaction (PCR). The primers were as follows: *pncA*-5ʹ-AACAGTTCATCCCGGTTC and *pncA*-3ʹ-GCGTCATGGACCCTATATC;*rpsA*-5ʹ-CGGAGCAACCCAACAATA and *rpsA*-5ʹ-GTGGACAGCAACGACTTC; and *panD*-5ʹ-TCAACGGTTCCGGTCGGCTGCT and *panD*-3ʹ-TATCCGCCACTGCTGCACGACCTT. The 20μL PCR mixture was prepared as follows: 10 μl of 2 × GoldStar MasterMix (CWBIO Biotech Company, China), 5 μL of DNA template, and 0.2 μM of each primer set. The PCR conditions for amplification were 5 min at 94°C, followed by 35 cycles of 94°C for 1 min, 59°C for 1 min, 72°C for 1 min, and a final extension of 72°C for 10 min. The PCR products were sent to Shanghai Sangon Biotech Company for sequencing. All of the sequence results were aligned with the *pncA, rpsA*, and *panD*genes from reference strain H37Rv (GenBank accession no. NC000962) using DAMAN(version6.0) software.

Genotyping {#s0002-s2004}
----------

Spoligotyping analysis was performed in accordance with the previous literature.[@cit0018] Briefly, the primers DR3ʹ-CCGAGAGGGGACGGAAAC and DR5ʹ-GGTTTTGGGTCTGACGAC were used for PCR of the extracted genome samples, and then the PCR products were hybridized with a membrane precoated with 43 spacer oligonucleotides to determine the results. The spoligotyping results were aligned through the SITVITWEB website ([<http://www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE/>]{.ul}). The primersNTF-5ʹ-CCAGATATCGGGTGTGTCGACandNTF-3ʹ-TGCCGTTCTCGAAATCTAAACAA were designed based on the NTF (nuclear transcription factor) region of *M. tuberculosis*.[@cit0019] The strain was defined as "modern-type" in the presence of the IS6110 insertion or "ancient type" in the absence of theIS6110 insertion according to a previous report.[@cit0020]

Data Analysis {#s0002-s2005}
-------------

SPSS software, version 19.0, was used for data analysis, and the chi-square test was performed to analyse the correlations between categorical variables.*P*\<0.05 was considered statistically significant.

Results {#s0003}
=======

PZA Susceptibility Testing and Patients Demographics {#s0003-s2001}
----------------------------------------------------

In this study, a total of 152 MDR-TB strains were included, and 105 (69.02%) were resistant to PZA. Moreover, 43 of the152 strains (28.29%) were pre-extensively drug resistant (pre-XDR), 37 (86.04%) were PZA resistant; and 25 (16.44%) were XDR, 23 (92%) were PZA resistant. In addition, 102 (71.71%) strains were resistant to all four first-line anti-tuberculosis drugs, and 82 (80.39%) were resistant to PZA. These results showed that pre-XDR strains, XDR strains, and strains resistant to all four first-line drugs were more likely to develop PZA resistance.

Of the 152 MDR strains, 119 (78.28%) were resistant to streptomycin, 85 (55.92%) were resistant to ethambutol, 35 (23.02%) were resistant to kanamycin, 63 (41.44%) were resistant to levofloxacin, 35 (23.02%) were resistant to amikacin, 25 (16.45%) were resistant to capreomycin, 23 (15.13%) were resistant to prothionamide, and 15 (9.86%) were resistant to p-aminosalicylic acid ([Table 1](#t0001){ref-type="table"}). MDR strains that were resistant to ethambutol, streptomycin, and levofloxacin were more likely to develop PZA resistance.Table 1PZA Resistance in Different Groups of MDR-TB PatientsCharacteristicsNo. of Isolates\
(n=152)No. of PZA Resistant Isolates (n=105)No. of PZA Susceptible Isolates (n=47)OR95% CI*P* valueAge \<202818100.770.32--1.850.65 21--403926130.860.39--1.870.69 41--606145161.430.71--2.970.32 \>60241680.880.34--2.220.81Sex Female5128231.00 (reference) Male10177242.641.29--5.400.01Treatment History New case4320231.00 (reference) Retreated10985244.071.92--8.63\<0.001Drug resistance to0 Ethambutol8566192.451.23--5.040.01 Streptomycin11990293.7241.67--8.31\<0.001 Kanamycin3525101.1560.50--2.650.84 Levofloxacin6353102.391.17--4.890.02 Capreomycin251780.9420.37--2.371 P-aminsalicylic acid151323.1790.69--14.700.15 Protionamide231671.0270.39--2.691 Amikacin3523120.820.37--1.830.68 All four first-line drug resistant10982272.641.26--5.540.01 Pre-extensive-drug resistant^a^5343102.571.15--5.710.02 Extensive-drug resistant^b^272527.031.59--31.07\<0.001Spoligotyping Beijing family12797306.872.70--17.50\<0.001 T family^c^10640.6521.07--2.420.49 Other family142 ^d^12 ^e^0.0570.01--0.27\<0.001NTF type Ancestral type3412221.00(reference) Modern type11893256.822.97--15.45\<0.001[^1]

We further analysed the correlation between PZA resistance and clinical information, including sex, age, close contact history with tuberculosis patients, previous treatment, and tuberculosis genotype. The results showed that the PZA resistance rate was significantly higher among men than women (odds ratio (OR): 2.64, 95% confidence interval (CI): 1.29--5.40, *P*= 0.009), and the percentage of retreated MDR-TB patients in the PZA-resistant group was significantly higher than in the PZA-susceptible group (OR: 4.07,95% CI: 1.92--8.83, *P*\<0.001). Analysis of the correlations between the genotypes of these strains and PZA resistance showed that the Beijing family had a higher frequency of PZA resistance than other genotypes and that modern-type strains were more likely to develop PZA resistance than ancient type strains.

Mutations in MDR Strains {#s0003-s2002}
------------------------

The *pncA* genes of 152 strains were sequenced and analysed, and the data showed that the PZA susceptibility results were consistent with the *pncA* mutation for 133 strains. Eight PZA-susceptible strains harboured *pncA* mutations, including three synonymous mutations. Eleven strains were resistant by the test of MGIT960 but harboured no *pncA* mutations. As a result, with PZA susceptibility phenotype as the gold standard, *pncA* mutation detection showed sensitivity of 89.52% (95% CI, 81.64--94.39%) and specificity of 89.36% (95% CI, 76.10--96.01%) in predicting PZA resistance.

Of the 152 MDR strains, 50 harboured no mutations, and102 harboured *pncA* mutations, of which 82 strains had base mutations (including three nonsense mutations and three synonymous mutations), and 20 had frame shift mutations. Moreover, 13 strains harboured multiple mutations, including double mutations in eight strains, triple mutations in three strains, and four mutations in two strains. The remaining 89 strains harboured a single *pncA* mutation, either a single base mutation or a synonymous mutation ([Table 2](#t0002){ref-type="table"}).Table 2Correlation between *pncA* Mutation Patterns and PZAResistanceNo. of PZA SusceptibleNo.of PZA ResistantTotalNo mutation391150Single mutation58186Silent mutation303Multiple mutation01313Total47105152

Different mutation patterns were detected in these resistant strains, including 14 insertions, 6 deletions, and 80 point mutations. These mutations were scattered throughout the entire length of the *pncA* gene, including the promoter region. Seven strains harboured a mutation in the promoter region of *pncA*, including an insertion of Gat locus −7 for one strain, a T to C nucleotide substitution at locus −11 for five strains, and an A to G transition at locus −12 for one strain. For the remaining 95 strains, *pncA* mutations were found in the open reading frame. Three strains harboured a large segment deletion, including deletions of codons 79 to 92, codons 189 to 218, and codons 196 to 221. In this study, we detected 32 new mutations that were not found in the GMTV and TBDReaMDB databases or reported in previous studies, including 16 substitution mutations and16 frame shift mutations ([Table 3](#t0003){ref-type="table"}).Table 3Mutant Profiles of MDR-TB Isolates Within *pncA*Nucleotide PositionNucleotide ChangeAmino Acid PositionAmino Acid ChangeNo. of IsolatesSubstitution1−12T to CPromoter--52−11A to GPromoter--133ATG to ATA1Met to Ile1411TTG to TCG4Leu to Ser1514ATC to AGC5Ile to Ser1619GTC to TTC7Val to Phe2720GTC to GGC7Val to Gly1824GAC to GAA8Asp to Glu1924GAC to GAG8Asp to Glu11026GTG to GCG9Valto Ala21126GTG to GGG9Val to Gly11228CAG to TAG10Gln to Stop11329CAG to CCG10Gln to Pro11435GAC to GCC12Asp to Ala21535GAC to GGC12Asp to Gly11637\*TTC to GTC13Phe to Val11740\*TGC to GGC14Cys to Gly11840TGC to CGC14Cys to Arg11941TGC to TAC14Cys to Tyr12050GGC to GAC17Gly to Asp12156CTG to CCG19Leu to Pro12262GTA to GGA21Val to Gly32371GGC to GAC24Gly to Asp12477GCG to GGG26Ala to Gly12583GCC to GAC28Ala to Asp12694TTC to GTC32Phe to Val127104CTG to CCG35Leu to Pro128105\*CTG to CTC35Leu to Pro129123TAC to TAG41Tyr to Stop130128CAC to CCC43His to Pro131136GCA to CCA46Ala to Pro132145GAC to AAC49Asp to Asn133146GAC to GGC49Asp to Gly134146GAC to GCC49Asp to Ala135152CAC to CGC51His to Arg136160CCG to TCG54Pro to Ser137161\*CCG to CGG54Pro to Arg138161CCG to CAG54Pro to Glu139170\*CAC to CGC57His to Arg140171CAC to CAA57His to Gln141172TTC to GTC58Phe to Val142185CCG to CGG62Pro to Arg143194\*TCC to TGC65Ser to Cys144196TCG to CCG66Ser to Pro145202TGG to CGG68Trp to Arg146203TGG to TCG68Trp to Ser147203TGG to TAG68Trp to Stop248212CAT to CGT71His to Arg149212\*CAT to CCT71His to Pro150226ACT to CCT76Thr to Pro451254CTG to CGG85Leu to Arg152269\*ATC to ACC90Ile to Thr153287AAG to AGG96Lys to Arg154290GGT to GAT97Gly to Asp155305GCG to GTG102Ala to Val156308TAC to TGC103Tyr to Cys157314GGC to GAC105Gly to Asp158317\*TTC to TCC106Phe to Ser159359CTG to CGG120Leu to Arg760374GTC to GGC125Val to Gly161374\*GTC to GCC125Val to Ala162398ATT to ACT133Ile to Thr263407GAT to GGT136Asp to Gly164412TGT to CGT138Cys to Arg165416GTG to GGG139Val to Gly266424ACG to CCG142Thr to Pro167425ACG to ATG142Thr to Met168437GCG to GTG146Ala to Val169463GTG to ATG155Val to Met170466\*CTG to TTG154Leu to Leu171467\*CTG to CAG156Leu to Gln172467CTG to CCG156Leu to Pro173478ACA to CCA160Thr to Pro174511GCG to ACG171Ala to Thr175511GCG toCCG171Ala to Arg176519\*GAG to GAA173Glu to Glu177535\*AGC to TGC179Ser to Cys278541\*GAG to TAG181Glu to Arg179543GAG to GAT181Glu to Arg180555\*AGC to AGT185Ser to Ser1deletion8179 to 92\*CTGGCCCGCGCCAT deletion27Frameshift182189 to 218\*CTATTCCTCGTCGTGGCCACCGCATTGCGT deletion63Frameshift183196 to 221\*TCGTCGTGGCCACCGCATTGCGTCAG deletion64Frameshift184200\*C deletion84Frameshift185246\*T deletion141Frameshift186329A deletion110Frameshift1insertion87−7\*G insertionpromoter--188121\*ACG insertion41Asp insertion189130\*AG insertion44Frameshift190201\*GT insertion67Frameshift191240\*CGGA insertion81Frameshift192253\*C insertion85Frameshift193256\*G insertion86Frameshift194268\*T insertion90Frameshift295391G insertion131Frameshift196392GG insertion131Frameshift197411\*TG insertion137Frameshift198417\*AG insertion140Frameshift199447\*T insertion150Frameshift1100534\*G insertion179Frameshift1Multiple mutations111,478, 535,541TTG to TCG, ACA to CCA, AGC to TGC, GAG to TAG4,160,179,181Leu to Ser, Thr to Pro, Ser to Cys, Glu to Arg1224,35, 254, 412GAC to GAA, GAC to GCC, CTG to CGG, TGT to CGT8,12,85,138Asp to Glu, Asp to Gly, Leu to Arg, Cys to Arg13105,121,\
203CTG to CTC, ACG insertion, TGG to TCG35,44Leu to Pro, Aspinsertion,Trp to Ser1426,40,398GTG to GCG, TGC to GGC, ATT to ACT9,14,133Val to Ala, Cys to Gly, Ile to Thr1556,145,463CTG to CCG, GAC to AAC, GTG to ATG19,49,155Leu to Pro, Asp to Asn, Val to Met1619,437GTC to TTC, GCG to GTG71,46Val to Phe, Ala to Val1777,171GCG to GGG, CAC to CAA26,57Ala to Gly, His to Gln1840,104TGC to CGC, CTG to CCG14,35Cys to Arg, Cys to Arg1937,128,TTC to GTC, CAC to CCC13,43Phe to Val, His to Pro110160,253CCG to CTG, C insertion54,85Pro to Ser, Frameshift111196,212TCG to CCG, CAT to CCT66,71Ser to Pro, His to Pro11229,287CAG to CCG, AAG to AGG10,96Gln to Pro, Lys to Arg113161,200CCG to CGG, C deletion54,84Pro to Arg, Frameshift1[^2]

The mutations of *pncA* in MDR strains from Henan were diverse. The PZA-resistant strains harboured 100 different mutant types, nine of which were found in multiple strains ([Table 3](#t0003){ref-type="table"}). Specifically, codon 359 was associated with the highest mutation rate, and its mutation (Leuto Arg) was found in eight strains (12.3%). Locus-11 of the *pncA* promoter was associated with the second highest mutation rate; this mutation was found in five strains. Codon 226 mutations (Thr to Pro) were found in four strains (6.8%). In addition, six mutant types were found in two drug-resistant strains.

Eight PZA-susceptible strains harboured *pncA* mutations, including three synonymous mutations. It should be noted that A to T substitution at codon 535 was found in both PZA-resistant and PZA-sensitive strains. PZA susceptibility tests and *pncA* sequencing were repeated for these strains, and the results remained the same. The MICs of PZA were determined with7H9 liquid medium (pH 5.5) for these eight strains. The results showed that the MIC was 12.5μg/mL for three strains with a synonymous mutation, 25 μg/mL for two trains, and 50μg/mL for three strains, which included the strain with a codon535 mutation ([Table 4](#t0004){ref-type="table"}).Table 4MIC of PZA-Susceptible Strains Harbouring *pncA* Mutation(s)Nucleotide PositionNucleotide ChangeAmino Acid PositionAmino Acid ChangeNo. of IsolatesMIC\
(μg/mL)11TTG to TCG4Leu to Ser125424ACG to CCG142Thr to Pro150478ACA to CCA160Thr to Pro125535^a^AGC to TGC179Ser to Cys150541GAG to TAG181Glu to Arg150466^b^CTG to TTG154Leu to Leu112.5519^b^GAG to GAA173Glu to Glu112.5555^b^AGC to AGT185Ser to Ser112.5[^3]

Strains without *pncA* mutations could have other mechanisms for PZA resistance. Therefore, other genes associated with PZA resistance were sequenced, including *rpsA* and *panD* ([Table 5](#t0005){ref-type="table"}). No mutations were detected in the promoter regions of *rpsA* and *panD*, and most PZA-resistant strains harbour in g*rpsA* or *panD* mutations were also accompanied by *pncA* mutations. In this study, 72.4% (76/105) of PZA-resistant and 74.5% (35/47) PZA-susceptible clinical strains had eight and one point mutations within their *rpsA* genes, separately. *RpsA* mutations were scattered, although most mutations were located in the180amino acids of the N-terminus and C-terminus. Notably, no *pncA* mutations were detected in PZA-resistant strains harbouring *rpsA* codon357 and codon532 mutations. The CGA to CGC synonymous mutation in *rpsA* codon 212is a non-specific mutation that occurred in both the 68PZA-resistant strains and the 35PZA-susceptible strains. Spoligotyping analysis showed that 96 (93.2%) of the 103 strains with a synonymous *rpsA* mutation belonged to the Beijing family and that two strains belonged to the T family. The *rpsA* nonsynonymous mutation frequencies among PZA-resistant XDR strains and MDR strains were 8% (2/25) and 5.5% (6/109), respectively. The XDR strains had a greater tendency to harbour *rpsA* mutations than the MDR strains. No *panD* mutations were detected in the 47PZA-susceptible strains. Two of the 105PZAdrug-resistant strains harboured *panD* mutations, and one of these strains harboured no *pncA* mutations.Table 5Mutant Profiles of *rpsA* and *panD* among MDR-TB IsolatesNucleotide PositionNucleotide ChangeAmino Acid PositionAmino Acid ChangeNo. of Isolates*pncA* Nucleotide Change(Amino Acid Change)PZA resistant isolates*rpsA*93^a^AAG to AAC31Lys to Asn2T20G (Val7Gly), A212G (His71Pro)357 ^a,\ b^CTC to CGC119Leu to Arg1wild-type368GAC to GCC123Asp to Ala1C171A(His57Gln)532^a,b^AAG to GAG178Lys to Glu1wild-type630^a^ACC to AGC210Thr to Cys1G50A(Gly17Asp)636^c^CGA to CGC212Arg to Arg68949^a^ATC to GTC317Ile to Val1C161G(Pro54Arg)1235GCC to GTC412Ala to Val1G145A(Asp49Asn)*panD*167GTC to GCC56Val to Ala1T40G(Cys14Gly)389^b^GAG to GGG130Glu to Gly1wild-typePZA susceptible isolates*rpsA*636CGA to CGC212Arg to Arg35wild-type[^4]

To evaluate the efficiency of DNA sequencing for PZA resistance, we compared the sequencing results and the resistance phenotype ([Table 6](#t0006){ref-type="table"}). With the resistance phenotype as a reference, detection of mutations in *pncA* alone showed sensitivity of 89.52% (95% CI, 81.64--94.39%) and specificity of89.36% (95% CI, 76.10--96.01%); the kappa was 0.76 between the *pncA* mutation and PZA resistance. The concordance between sequencing of *rpsA/panD* and PZA resistance was low, indicating a low diagnostic value for PZA resistance on its own. However, the combination of *rpsA* and *panD* mutations with *pncA* sequencing increased the sensitivity for PZA resistance from 89.52% (95% CI, 81.64--94.39%) to 92.38% (95% CI, 85.54--96.65%) and increased the kappa to 0.80.Table 6Efficacy Evaluation of Sequencing for PZA Resistance in MDR StrainsgenePZA Resistant (n=105)PZA Susceptible (n=47)Sensitivity (%)\
(95% CI)Specificity (%)\
(95% CI)Kappa CoefficientSubstitutions Mutation and IndelNo Mutation and Synonymous MutationSubstitutions Mutation and IndelNo Mutation and Synonymous Mutation*pncA*941154289.52 (81.64--94.39)89.36 (76.10--96.01)0.76*rpsA*7980476.67 (2.94--13.68)100 (92.45--100.00)0.07*panD*21030471.90 (0.23--6.70)100 (92.45--100.00)0.01*pncA/rpsA/panD*97854292.38 (85.54--96.65)89.36 (76.10--96.01)0.8

Relationship Between Treatment outcome and PZA Susceptibility Phenotype {#s0003-s2003}
-----------------------------------------------------------------------

To investigate the effect of PZA resistance on treatment outcome, we followed up the patients for 24 months to obtain clinical information. Nine patients failed to provide complete treatment information, including two deaths, two refusals to followup, and five losses. The data showed that after treatment, 93 (93.93%) of the 99 PZA-resistant patients showed sputum smear/culture conversion, while 42 (95.45%) of the 44PZA-susceptible patients showed sputum smear/culture conversion ([Table 7](#t0007){ref-type="table"}). These results indicated no significant difference in sputum conversion rate between PZA-resistant and susceptible patients. However, when the sputum conversion time was segmented and compared with PZA resistance, the results showed that at the end of 6months of treatment, the sputum smear/culture conversion rate was 1.08% in PZA-resistant patients, which was significantly lower than that in PZA-susceptible patients (7.14%) ([Table 7](#t0007){ref-type="table"}), indicating that PZA resistance could affect the time to sputum smear/culture conversion.Table 7Correlation Between Treatment Outcome and Drug Susceptibility for PZATreatment OutcomePZA SuspustiblePZA ResistantChi-Squarep valueNumber of PatientsPercent of Patients (%) (95% *CI*)Number of PatientsPercent of Patients (%) (95% *CI*)Sputum conversion Yes4295.45 (84.52--99.44)9393.93 (87.26--97.74)0.711 No24.54 (0.55--14.57)66.06 (2.26--12.72)Sputum conversion time 6 months after treatment37.14 (1.05--19.48)11.08 (0.03--5.84)10.010.018 12 months after treatment1433.33 (19.56--49.55)2021.51 (13.65--31.23) 18 months after treatment2150 (34.19--65.81)4548.39 (37.89--58.98) 24 months after treatment49.52 (2.65--22.62)2729.03 (20.08--39.36)

Discussion {#s0004}
==========

PZA plays an important role in the treatment of patients with MDR-TB.[@cit0021],[@cit0022] In this study, we investigated PZA resistance in MDR-TB patients in Henan and analysed the correlations between PZA resistance and mutations in PZA resistance-related genes. The results showed that 69% (95% CI, 57.8--71.8%) of MDR strains were PZA resistant, which was similar to that in the Chongqing area (62.4%)[@cit0023] and slightly higher than those in previous reports.[@cit0024]--[@cit0027] This study showed that retreated MDR-TB patients were more likely to develop PZA resistance (78.0% vs 46.5%), suggesting a correlation between a history of tuberculosis and PZA resistance. The higher PZA resistance rate observed in retreated MDR-TB patients could be related to their previous treatment regimens with PZA. As a result, the role of PZA should be carefully considered in the treatment of MDR-TB patients. It was necessary to perform PZA susceptibility tests to develop an optimal treatment regimen for MDR-TB patients.

Previous reports have revealed a correlation between PZA resistance and fluoroquinolone resistance.[@cit0028]--[@cit0030] Similarly, our study showed that PZA resistance was associated with resistance to other anti-tuberculosis drugs, including EMB, SM and OFLX. When exposed to antibiotics such as rifampicin, fluoroquinolones, and aminoglycosides, bacteria will induce the generation of free oxygen radicals in the body and increase the frequency of gene mutations. Given the prolonged use of anti-tuberculosis drugs by MDR-TB patients, we hypothesized that prolonged drug exposure could induce more genetic mutations in *M. tuberculosis*, eventually leading to cross-resistance to PZA and other drugs.

The genotyping results showed that PZA resistance rates were significantly higher in the Beijing family of *M. tuberculosis* than in the non-Beijing family, and PZA resistance rates were higher in the modern subline ages than in the ancient sub line ages. In this study, approximately76.3% of Beijing family and 60% of T family strains harboured PZA resistance, the frequency was significantly higher than those among other genotypes (14.3%). However, due to the small sample size, we were unable to reach any definitive conclusions about correlations with *M. tuberculosis* genotypes, whereas previous studies have shown that PZA resistance was not associated with the genotype.[@cit0031]

In this study, the concordance rate was 91.4% between PZA-resistant phenotypes and *pncA* sequences, with discordant results for 13 strains. Eight strains with a *pncA* mutation, including three strains with a synonymous mutation, were susceptible to PZA, while eight strains with wild-type *pncA* were resistant to PZA. To exclude experimental errors, we repeated PZA susceptibility tests for these 13 strains and obtained the same results. The spoligotypes of 16 strains with inconsistent results between resistance and *pncA* gene mutations were analysed, and the results showed that 14 strains belonged to the Beijing genotype and two strains to the T family. We further determined the MICs of PZA-susceptible strains with *pncA* mutations. Except for three strains with a synonymous mutation, the remaining five strains showed low-level PZA resistance (12.5 μg/mL \<MIC≤50μg/mL). Drug resistance is the result of the interactions of multiple macromolecules in organisms, including genes, transcripts, and proteins. In addition, some genetic mutations might not necessarily lead to a drug resistance phenotype.[@cit0032],[@cit0033]

The *pncA* mutation rate in PZA-resistant strains varies among different regions, eg, 45.7% in Brazil,[@cit0034] 70.6% in Iran,[@cit0035] 75.0% in Taiwan,[@cit0036] 88% in Chongqing,[@cit0023] and 94.1% in Sweden.[@cit0037] In this study, 89.52% of the PZA-resistant strains harboured *pncA* mutations. The 102 mutant strains harboured 100 different mutation types (including synonymous mutations) that were scattered throughout the *pncA* gene. Substitution mutations and frame shifts (due to insertion or deletion) were detected in both the open reading frames and promoter regions of *pncA*. In this study, we detected 32 new mutations.[@cit0038]--[@cit0042] In addition, 89 of the100mutations were found in only one strain, and the remaining 11 mutations, which contained 35 strains, were shared mutations. Mutations in the promoter region were associated with PZA resistance.[@cit0043],[@cit0044] Seven strains harboured mutations in the promoter region, which down-regulated the *pncA* transcription level, reduced PZ as activity, and ultimately led to PZA resistance. All three strains with a synonymous mutation belonged to the Beijing family. Moreover, out of 35 strains with shared mutations, 28 strains belonged to the Beijing genotype, six strains belonged to the T1 genotype, and one strain belonged to the T2 genotype. Sixteen strains with shared mutations had the same spoligotype and were genetically clustered. It was found that three of five strains with the promoter substitution mutation (T-12C) and five of seven strains with a substitution mutation at codon 359 were genetically in the Beijing family. Similar genetic classifications were found for substitution mutations at codon 226 (two of four isolates belonging to Beijing family), codon 203 (Beijing family), codon 398 (T family) and codon 416, and all of them were phenotypically resistant. Previous studies have suggested a correlation between *pncA* mutations and gene clustering,[@cit0012],[@cit0045],[@cit0046] but we were unable to determine gene clustering due to the small sample size and the dominant Beijing genotype.

The11strains without *pncA* mutations could involve other mechanisms of PZA resistance;[@cit0011],[@cit0013],[@cit0015] therefore, *panD* and *rpsA* mutations were analysed in this study. In 2011, Shi et al reported that *rpsA* could be another PZA resistance-related gene.[@cit0013] However, limited data are available to explain the relationship between *rpsA* mutations and PZA susceptibility; thus, the contribution of the *rpsA* mutations conferring PZA resistance has been controversial until now. Alexander et al found no *rpsA* mutations in PZA-resistant isolates but one *rpsA* protein mutation (A364G) in 13 PZA-sensitive strains;[@cit0047] Bhuju et al did not find any *rpsA* mutations among either PZA-resistant isolates or PZA-susceptible isolates.[@cit0034] In addition, Pang et al found no genetic mutations associated with PZA resistance in the *rpsA* gene among MDR-TB patients.[@cit0023] In this study, the*rpsA*mutation frequency (6.7%) in MDR strains was higher than in these reports. A high synonymous mutation frequency was observed at codon212in both PZA-resistant and PZA-susceptible strains. However, no missense or deletion/insertion mutations in *rpsA* were detected in PZA-susceptible strains. Tan et al reported three nonsynonymous mutations in the *rpsA* C-terminal region;[@cit0048] Gu et al also identified seven of 26 mutations occurring in the C-terminal region.[@cit0024] Moreover, Khan's research found that the majority of *rpsA* mutations were located in nucleotides 973--1051 of the coding region, especially nucleotides 1024--1030.[@cit0049] In line with previous reports, we detected a mutation hotspot at the C-terminus of *rpsA*. Moreover, five of the eight *rpsA* mutations have never been described in previous studies, so further research is needed to investigate the effects of these new mutations on PZA resistance. In addition, the XDR strains in this study had a greater tendency to harbour *rpsA* mutations than the MDR strains, also demonstrating that *rpsA* mutations might be related to PZA resistance. While previous studies have shown that *panD* is a target for PZA resistance in *M. tuberculosis*, few studies have been conducted to investigate *panD* mutations in clinical strains. This study showed that two (1.9%)PZA-resistant strains harboured a *panD* mutation, one of which had wild-type *pncA*. In summary, we identified eight PZA-resistant strains without any known mutations, indicating that additional unknown mechanisms are involved in PZA resistance and requiring further research. For PZA resistance, the combination of all three genes sequenced achieved sensitivity of 92.38% and specificity of 89.36%, consistent with other reports. Considering the insufficient reliability and inconsistency between phenotypes and the drug susceptibility test, the sequencing of all three PZA-resistant genes could evaluate the resistance of PZA more effectively.

Finally, we analysed the outcomes of 124 patients under different treatment regimes. The sputum smear/culture conversion rate was slightly higher in PZA-sensitive patients than in PZA-resistant patients (95.5%vs93.9%), but the difference was not statistically significant. However, subgroup analysis showed that at the end of 6 months of treatment, the sputum smear/culture conversion rate was significantly higher in PZA-sensitive MDR-TB patients than in PZA-resistant patients (7.14%vs1.08%), suggesting that PZA resistance prolonged the time to sputum smear/culture conversion.

This study had several limitations. First, the sample size was small, and all of the strains were derived from our region. As a result, the results might not be representative and might not apply to other regions; therefore, more samples are needed in the future. Second, we detected 32 new *pncA* mutations and five new *rpsA* mutations, and further research is needed to investigate their effects on PZA resistance.

In summary, this study was the first to investigate the molecular characterization ofPZA resistance in MDR strains from Henan. The results showed that PZA resistance was substantially related to *pncA* mutations, which were scattered and diverse. In addition, *rpsA* and *panD* mutations were related to PZA resistance only in MDR strains without *pncA* mutations. With the resistance phenotype as the reference, molecular diagnosis with the combination of *pncA, rpsA*, and *panD* achieved sensitivity of98.1% and specificity of92.3%. Given the high PZA resistance rate in MDR-TB patients and that PZA resistance prolonged the time to sputum smear/culture conversion, the effects of PZA should be considered carefully for MDR-TB patients in high TB burden regions. In conclusion, the combination of *pncA, rpsA*, and *panD* enabled rapid and accurate prediction of PZA resistance, helped guide the use of PZA and optimized treatment therapy for MDR-TB patients in Henan.
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[^1]: **Notes:** ^a^Pre-XDR strains: MDR strains that were also resistant to levofloxacin or any injectable drug (kanamycin, capreomycin, amikacin). ^b^XDR strains: MDR strains that were also resistant to levofloxacin and any injectable drug (kanamycin, capreomycin, amikacin). ^c^Including the T1, T2, and T3 genotypes. ^d^Two strains in the MANU2 family. ^e^Seven strains in the MANU2 family, four in the H3 family, and one with an unknown genotype.

[^2]: **Note:** \*Not found in the TBDRM and GMTV databases or in previous studies.

[^3]: **Notes:** ^a^Present in both PZA-resistant and PZA-susceptible strains. ^b^Synonymous mutation.

[^4]: **Notes:** ^a^New mutations. ^b^No *pncA* mutations. ^c^Also present in PZA-susceptible strains.
